Nick Redfearn and Fabrice Mattei discuss how to compromise between improving access to vaccines whilst also protecting research and pharma innovation.

The World Trade Organisation (WTO) has finally adopted the long awaited Ministerial decision no. WT/MIN(22)/30 (“WTO Decision”) on 17 June 2022, wherein WTO Member States may grant a patent waiver to address the inequality in accessing to covid-19 vaccines.

For the government leaders and ministers, the result signifies a giant step in the right direction, given the unanimity required for the decision and the time constraint given. However, the ruling left others, particularly lower income countries, unsatisfied.

In May of this year, the World Health Organisation (WHO) reported only 16 per cent of people in ...

This article is part of a subscription-based access, to continue reading, please contact your library